• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

[骨质疏松症的治疗目的与治疗指南]

[Therapeutic purpose and treatment guideline of osteoporosis].

作者信息

Ogawa Sumito, Ouchi Yasuyoshi

机构信息

Department of Geriatric Medicine, The University of Tokyo, Japan.

出版信息

Clin Calcium. 2012 Jun;22(6):885-9.

PMID:22653029
Abstract

The purpose of osteoporosis treatment is mainly for maintenance of bone health and QOL as well as for fracture prevention, and pharmacological intervention, improvement of risk factors including lifestyle, utilization of FRAX® are important in practice. Recently, treatment guideline of osteoporosis is revised in the Japanese guidelines for the prevention and treatment of osteoporosis.

摘要

骨质疏松症治疗的目的主要是维持骨骼健康和生活质量以及预防骨折，在实际应用中，药物干预、改善包括生活方式在内的风险因素、使用FRAX®工具很重要。最近，日本骨质疏松症防治指南对骨质疏松症治疗指南进行了修订。

相似文献

1
[Therapeutic purpose and treatment guideline of osteoporosis].[骨质疏松症的治疗目的与治疗指南]
Clin Calcium. 2012 Jun;22(6):885-9.
2
[Clinical application of FRAX® in Japan].FRAX®在日本的临床应用
Clin Calcium. 2012 Jun;22(6):857-63.
3
[Absolute risk for fracture and WHO guideline. Fracture risk assessments recommended by World Health Organization and Japanese guidelines for prevention and treatment of osteoporosis 2006].[骨折的绝对风险与世界卫生组织指南。世界卫生组织推荐的骨折风险评估以及《2006年日本骨质疏松症防治指南》]
Clin Calcium. 2007 Jul;17(7):1022-8.
4
[Current approach to osteoporosis].[骨质疏松症的当前治疗方法]
Clin Calcium. 2013 Jan;23(1):75-82.
5
[On "2015 Guidelines for Prevention and Treatment of Osteoporosis". Overview and the aim of the treatment of osteoporosis].
Clin Calcium. 2015 Sep;25(9):1273-7.
6
[Japanese Guidelines for the Prevention and Treatment of Osteoporosis (2006 Edition) and its significance].[日本骨质疏松症防治指南（2006年版）及其意义]
Nihon Rinsho. 2007 Nov 28;65 Suppl 9:29-34.
7
[Epidemiology of bone and joint disease - the present and future - . Risk and prevention/treatment of fractures associated with lifestyle-related diseases].[骨与关节疾病的流行病学——现状与未来——与生活方式相关疾病相关骨折的风险及预防/治疗]
Clin Calcium. 2014 May;24(5):733-42.
8
Health-related quality of life (HRQOL) in Japanese osteoporotic patients and its improvement by elcatonin treatment.日本骨质疏松症患者的健康相关生活质量（HRQOL）及其通过依降钙素治疗的改善情况。
J Bone Miner Metab. 2005;23(2):167-73. doi: 10.1007/s00774-004-0556-5.
9
[Daily practice using the guidelines for prevention and treatment of osteoporosis. Fracture risk assessment with Japanese guideline].[依据骨质疏松症防治指南进行日常实践。采用日本指南进行骨折风险评估]
Clin Calcium. 2008 Aug;18(8):1084-8.
10
[Daily practice using the guidelines for prevention and treatment of osteoporosis. Osteoporosis prevention and use of the new management guideline for osteoporosis].[按照骨质疏松症防治指南进行日常实践。骨质疏松症的预防及新的骨质疏松症管理指南的应用]
Clin Calcium. 2008 Aug;18(8):1096-103.

引用本文的文献

1
Gene Polymorphisms and the Bone Mineral Density Response to Alendronate Therapy in Postmenopausal Chinese Women with Low Bone Mass.基因多态性与低骨量绝经后中国女性阿仑膦酸盐治疗的骨密度反应
Pharmgenomics Pers Med. 2021 Dec 23;14:1669-1678. doi: 10.2147/PGPM.S344818. eCollection 2021.
2
Genetic polymorphisms in the mevalonate pathway affect the therapeutic response to alendronate treatment in postmenopausal Chinese women with low bone mineral density.甲羟戊酸途径中的基因多态性影响中国绝经后低骨密度女性对阿仑膦酸盐治疗的反应。
Pharmacogenomics J. 2015 Apr;15(2):158-64. doi: 10.1038/tpj.2014.52. Epub 2014 Sep 16.